Sentences with phrase «whether ovarian cancer patients»

Not exact matches

In order to assess whether an improved diet could reduce the risk of ovarian cancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women, Qin analyzed the diets of 415 women with ovarian cancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer and 629 control patients, using data from the African - American Cancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United SCancer Epidemiology Study, a population - based case - control study of ovarian cancer in African - American women in 11 sites in the United Scancer in African - American women in 11 sites in the United States.

Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer.

Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thCancer Center of the University of Pennsylvania shows PTEN may serve as a marker for whether a patient with BRCA 1 - 2 deficient ovarian cancer is likely to respond to checkpoint inhibitor thcancer is likely to respond to checkpoint inhibitor therapy.

Whether that will be restricted to patients with a homologous recombination deficiency or all ovarian cancer patients is probably going to depend on the particular combination.

An international research team, led by University College London's Professor Jonathan Ledermann, carried out a trial to see whether olaparib could have a role to play in preventing ovarian cancer from coming back in this group of patients.

The tests will detect whether the patient has any of the 26 genes that indicate they have a greater risk for developing breast, colon, ovarian, pancreatic and other cancers